Serascience gets EU green light for world’s first POC blood cancer test
This article was originally published in Clinica
Executive Summary
A point-of-care test for multiple myeloma, said to be the first of its kind, is poised to hit the EU markets, following the CE marking of the product by its UK developer Serascience.